

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 07 June 2000 (07.06.00)	
<b>International application No.</b> PCT/US99/21565	<b>Applicant's or agent's file reference</b> PF-0594 PCT
<b>International filing date (day/month/year)</b> 17 September 1999 (17.09.99)	<b>Priority date (day/month/year)</b> 18 September 1998 (18.09.98)
<b>Applicant</b> LAL, Preeti et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
18 April 2000 (18.04.00)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b> Juan Cruz Telephone No.: (41-22) 338.83.38
--	--

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PF-0594 PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/21565	International filing date (day/month/year) 17 SEPTEMBER 1999	Priority date (day/month/year) 18 APRIL 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): C07K 14/46; C12N 15/12 and US Cl.: 530/351; 435/6, 320.1, 252.3; 424/94.5; 536/23.5		
Applicant INCYTE PHARMACEUTICALS, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 18 APRIL 2000	Date of completion of this report 11 JULY 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  CHARLES PATTERSON
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21565

## I. Basis of the report

## 1. With regard to the elements of the international application:\*

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-74, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 75-76, as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages None, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_

## 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

## 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages None
- ☒ the claims, Nos. None
- ☒ the drawings, sheets/fig. None

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21565

## IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☒ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:

Please See Supplemental Sheet.

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☐ all parts.
- ☒ the parts relating to claims Nos. 1-15 and 19, SEQ ID NO: 2&18.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21565

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)

Claims 1-15 and 19 YESClaims None NO

Inventive Step (IS)

Claims 1-15 and 19 YESClaims None NO

Industrial Applicability (IA)

Claims 1-15 and 19 YESClaims None NO**2. citations and explanations (Rule 70.7)**

Claims 1-15 and 19, SEQ ID NO: 2 and 18 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the claimed polypeptide, polynucleotide or methods of the instant claims.

It is pointed out that the examiner did not have the benefit of a search report from Chapter 1 nor the instant sequences in a computer readable form. Therefore only a word search could be done. No references were found in this word search that disclose the instant invention or make it obvious.

NONE

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**IV. LACK OF UNITY OF INVENTION:**

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2, and 13.3 is not complied with for the following reasons:

As applicant was previously notified this International Preliminary Examining Authority has found plural inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-15 and 19, drawn to a polypeptide, a pharmaceutical composition comprising the polypeptide, a method of treating or preventing a disorder comprising administering the pharmaceutical composition, a polynucleotide, a method of detecting the polynucleotide, a vector containing the polynucleotide, a host cell containing the vector and a method of making the polypeptide comprising using the host cell.

Group II, claim 16, drawn to an antibody.

Group III, claim 17, drawn to an agonist.

Group IV, claim 18 and 20, drawn to an antagonist and a method of treating or preventing a disorder comprising administering the antagonist.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

SEQ ID NO: 2-16 and SEQ ID NO:18-32 of Group I, II, III and IV.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-IV are drawn to completely different and distinct chemical compounds.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The polypeptides of SEQ ID NO:2-16 and the polynucleotides of SEQ ID NO:18-32 are different and separate and distinct substances.

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, C12Q 1/68, C07K 16/18, A61K 38/17</b></p>	<b>A2</b>	<p>(11) International Publication Number: <b>WO 00/17355</b></p> <p>(43) International Publication Date: <b>30 March 2000 (30.03.00)</b></p>																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>(21) International Application Number: <b>PCT/US99/21565</b></p> <p>(22) International Filing Date: <b>17 September 1999 (17.09.99)</b></p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">60/172,226</td> <td style="width: 40%;">18 September 1998 (18.09.98)</td> <td style="width: 30%;">US</td> </tr> <tr> <td>60/131,321</td> <td>27 April 1999 (27.04.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">US</td> <td style="width: 40%;">60/172,226 (CIP)</td> <td style="width: 30%;"></td> </tr> <tr> <td>Filed on</td> <td>18 September 1998 (18.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/131,321 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>27 April 1999 (27.04.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</b></p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <b>LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230</b></p> </div> <div style="width: 48%;"> <p>Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US).</p> <p>(74) Agents: <b>BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</b></p> <p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p> </div> </div>			60/172,226	18 September 1998 (18.09.98)	US	60/131,321	27 April 1999 (27.04.99)	US	US	60/172,226 (CIP)		Filed on	18 September 1998 (18.09.98)		US	60/131,321 (CIP)		Filed on	27 April 1999 (27.04.99)	
60/172,226	18 September 1998 (18.09.98)	US																		
60/131,321	27 April 1999 (27.04.99)	US																		
US	60/172,226 (CIP)																			
Filed on	18 September 1998 (18.09.98)																			
US	60/131,321 (CIP)																			
Filed on	27 April 1999 (27.04.99)																			
<p>(54) Title: <b>HUMAN CYTOSKELETON ASSOCIATED PROTEINS</b></p> <p>(57) Abstract</p> <p>The invention provides human cytoskeleton associated proteins (CYSKP) and polynucleotides which identify and encode CYSKP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CYSKP.</p>																				

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, C12Q 1/68, C07K 16/18, A61K 38/17</b>		<b>A3</b>	(11) International Publication Number: <b>WO 00/17355</b>
			(43) International Publication Date: <b>30 March 2000 (30.03.00)</b>
(21) International Application Number: <b>PCT/US99/21565</b> (22) International Filing Date: <b>17 September 1999 (17.09.99)</b> (30) Priority Data: 60/172,226                      18 September 1998 (18.09.98)      US 60/131,321                      27 April 1999 (27.04.99)              US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US    60/172,226 (CIP) Filed on                                      18 September 1998 (18.09.98) US    60/131,321 (CIP) Filed on                                      27 April 1999 (27.04.99) (71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230</b>		Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). (74) Agents: <b>BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b> <b>Published</b> <i>With international search report.</i> (88) Date of publication of the international search report: <b>6 July 2000 (06.07.00)</b>	
(54) Title: <b>HUMAN CYTOSKELETON ASSOCIATED PROTEINS</b>			
(57) Abstract			
<p>The invention provides human cytoskeleton associated proteins (CYSKP) and polynucleotides which identify and encode CYSKP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CYSKP.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 99/21565

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12Q1/68 C07K16/18 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YASUHIKO KOYANO ET AL.: "Molecular cloning and characterization of CDEP, a novel human protein containing the Ezrin-like domain of the band 4.1 superfamily and the Dbl homology domain of Eho Guanine Nucleotide Exchange Factors." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, no. 2, 18 December 1997 (1997-12-18), pages 369-375, XP002124973 ORLANDO, FL US abstract page 370, right-hand column, paragraph 2 -page 372, left-hand column, paragraph 1; figure 2 page 372, right-hand column, paragraph 2 -page 374, left-hand column, paragraph 1 --- -/--</p>	1-16, 19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

8 December 1999

Date of mailing of the international search report

31.03.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21565

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 28458 A (CHUGAI SEIYAKU KABUSHIKI KAISHA) 10 June 1999 (1999-06-10) figure 1 & AU 12615 99 A -----	1-16,19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 21565

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 19  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☒ Claims Nos.: 17, 18, 20  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheets

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-20 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:2, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:18, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 2. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:3, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:19, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 3. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:4, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:20, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 4. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:5, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:21, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 5. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:6, variant.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:22, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 6. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:7, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:23, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 7. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:8, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:24, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 8. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:9, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:25, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 9. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:10, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:26, expression vector and host cell comprising the

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 10. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:11, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:27, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 11. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:12, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:28, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 12. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:13, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:29, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 13. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:14, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:30, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 14. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:15, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:31, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## 15. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:16, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:23, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17, 18, 20

Present claims 17, 18, 20, directed to agonists and antagonists relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 17, 18 and 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

### Information on patent family members

PCT/US 99/21565

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9928458 A	10-06-1999	AU 1261599 A	16-06-1999